Medication errors and adverse drug reactions (ADRs) are major health concerns globally, with ADRs being a leading cause of hospitalisations. In Malaysia, about 1 in 10 hospitalised patients experience an ADR, with over 30% of these incidents being preventable. These errors also come with a hefty financial cost, making the need for safer, more personalised prescribing practices urgent.

In response, Alpro Group, Malaysia’s largest prescription pharmacy chain, has partnered with AGTC Genomics, a leader in genetic testing for personalised medicine. This collaboration integrates Pharmacogenomics (PGx) and Nutrigenomics (NGx) services into everyday healthcare. The goal is to provide more accurate, effective, and personalised medication prescriptions, reducing the risk of ADRs and improving patient outcomes.

The partnership will leverage Alpro’s extensive pharmacy network and AGTC’s advanced genetic testing technologies. PGx will help tailor prescriptions based on individual genetic makeup, while NGx will offer personalized dietary recommendations based on genetic insights.

Prof. Leong Chee Onn, CEO of AGTC Genomics, emphasised the importance of providing patients with the right medication, at the right dose, and at the right time. Dr Ng Ming Lee, Medical Director of Alpro Clinic, added that this collaboration is a key step toward reducing medication errors and improving healthcare standards nationwide.

The partnership will also focus on educating the public about genetic testing through workshops and consultations. Malaysians can visit Alpro Pharmacies for genetic testing to better understand their genetics and discover the most suitable personalised medications.